Market Place
Sourcing Support
Dynavax Stockholders Elect All Director Nominees at 2025 Meeting
11 Jun 2025 //
PR NEWSWIRE
Glass Lewis Backs Deep Track`s Board Change at Dynavax
04 Jun 2025 //
BUSINESSWIRE
Dynavax to Present at William Blair`s Growth Stock Conference
28 May 2025 //
PR NEWSWIRE
Dynavax`s feud with investor heats up ahead of annual meeting
12 May 2025 //
FIERCE BIOTECH
Dynavax reports Q1 2025 results and new pipeline programs
06 May 2025 //
PR NEWSWIRE
Dynavax Emphasizes Superior Board Leadership for Value Creation
29 Apr 2025 //
PR NEWSWIRE
Dynavax to Report Q1 2025 Results, Host Call on May 6
22 Apr 2025 //
PR NEWSWIRE
Dynavax Files Preliminary Proxy Statement
03 Apr 2025 //
PR NEWSWIRE
Dynavax Announces Debt Refinancing and Stock Repurchase
06 Mar 2025 //
PR NEWSWIRE
Dynavax to Participate in Upcoming Investor Conferences
25 Feb 2025 //
PR NEWSWIRE
Dynavax Reports Q4 & FY24 Results, Provides FY25 Financial Guidance
20 Feb 2025 //
PR NEWSWIRE
Dynavax to Report Q4 & Full Year 2024 Financial Results
06 Feb 2025 //
PR NEWSWIRE
Dynavax Advances Board Refreshment Program
27 Jan 2025 //
PR NEWSWIRE
Dynavax Reports Preliminary Q4, Full-Year 2024 Financial Highlights
13 Jan 2025 //
PR NEWSWIRE
Dynavax to Present at 7th Annual Evercore HealthCONx Conference
26 Nov 2024 //
PR NEWSWIRE
Dynavax Announces $100 Million Accelerated Share Repurchase Program
11 Nov 2024 //
PR NEWSWIRE
Dynavax drops Tdap vaccine after mulling ph. 1 data, competition
09 Nov 2024 //
FIERCE BIOTECH
Dynavax Announces $200 Million Share Repurchase Program
07 Nov 2024 //
PR NEWSWIRE
Dynavax To Report Q3 Financial Results 2024 Results On Nov 7
24 Oct 2024 //
PR NEWSWIRE
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
27 Jun 2024 //
PR NEWSWIRE
Dynavax to Present at Upcoming Investor Conferences
28 May 2024 //
PR NEWSWIRE
US FDA declines expanded use of Dynavax`s hepatitis B insufficient data
15 May 2024 //
REUTERS
Dynavax Provides US Regulatory Update On HEPLISAV-B 4-Dose Hemodialysis Regimen
14 May 2024 //
PR NEWSWIRE
Dynavax: Q1 2024 Financial Results, Business Updates
08 May 2024 //
PR NEWSWIRE
Dynavax Reports Q1 2024 Results on May 8
24 Apr 2024 //
PR NEWSWIRE
Dynavax to Present at TD Cowen`s 44th Annual Health Care Conference
27 Feb 2024 //
PR NEWSWIRE
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results
08 Feb 2024 //
PR NEWSWIRE
Dynavax Announces Fourth Quarter and Full Year 2023 Financial Highlights
08 Jan 2024 //
PR NEWSWIRE
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
20 Nov 2023 //
PR NEWSWIRE
Dynavax Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
PR NEWSWIRE
Dynavax to Report Third Quarter 2023 Financial Results
26 Oct 2023 //
PR NEWSWIRE
Dynavax to Present at H.C. Wainwright 4th Annual Hepatitis B Virus Conference
19 Oct 2023 //
PR NEWSWIRE
Dynavax Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
PRESS RELEASE
Dynavax to Report Second Quarter 2023 Financial Results
20 Jul 2023 //
PR NEWSWIRE
Dynavax to Present at Upcoming Investor Conferences
30 May 2023 //
PR NEWSWIRE
Dynavax to Present at the JMP Securities Life Sciences Conference
08 May 2023 //
PR NEWSWIRE
Dynavax Reports First Quarter 2023 Financial Results
02 May 2023 //
PR NEWSWIRE
Dynavax to Report First Quarter 2023 Financial Results and Host Conference
18 Apr 2023 //
PR NEWSWIRE
Dynavax to Present at the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
PR NEWSWIRE
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B
28 Feb 2023 //
PR NEWSWIRE
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
PR NEWSWIRE
Dynavax Announces Uplisting to the Nasdaq Global Select Market
31 Jan 2023 //
PR NEWSWIRE
Dynavax Announces Preliminary Unaudited Fourth Quarter Financial Results
09 Jan 2023 //
PR NEWSWIRE
Dynavax to Present at Two Upcoming Investor Conferences
09 Nov 2022 //
PRNEWSWIRE
Dynavax to Report Third Quarter Financial Results
20 Oct 2022 //
PRNEWSWIRE
Dynavax to Present at H.C. Wainwright 3rd Annual Hepatitis B Virus Conference
14 Oct 2022 //
PRNEWSWIRE
Dynavax - First Participant Dosed in Evaluating an Adjuvanted Plague Vaccine
12 Sep 2022 //
PRNEWSWIRE
Dynavax to Present at the H.C. Wainwright Annual Global Investment Conference
08 Sep 2022 //
PRNEWSWIRE
Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference
25 May 2022 //
PRNEWSWIRE
Why Dynavax Stock Won on a Losing Monday for the Market
16 May 2022 //
FOOL
Dynavax to Present at the H.C. Wainwright Global Investment Conference
16 May 2022 //
PRNEWSWIRE
Dynavax Reports First Quarter 2022 Financial Results
05 May 2022 //
PRNEWSWIRE
Dynavax Reports Q4 and Full Year 2021 Financial Results
28 Feb 2022 //
PRNEWSWIRE
Dynavax to Present at the Cowen 42nd Annual Health Care Conference
23 Feb 2022 //
PRNEWSWIRE
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2022 //
PRNEWSWIRE
Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference
18 Nov 2021 //
PRNEWSWIRE
Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman
21 Oct 2021 //
PRNEWSWIRE
Dynavax, US DOD collaborate to develop recombinant plague vaccine
05 Oct 2021 //
PHARMABIZ
Dynavax, US DOD collaborate to develop recombinant plague vaccine
05 Oct 2021 //
PHARMABIZ
Dynavax and U.S. Department of Defense Announce Collaboration
04 Oct 2021 //
PRNEWSWIRE
